biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM
AXIM Biotechnologies
AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker AXIM. Primary therapeutic focus areas include Neuroblastoma, Hyperinflammation, Sepsis, craniopharyngioma, Del
18 East 50th Street, 5 Floor, New York, NY 10022, US HQ
2011 Founded
7 Employees
Public company Type
AXIM · NYSE Ticker
Company details
- Status
- Public
- HQ
- 18 East 50th Street, 5 Floor, New York, NY 10022, US
- Founded
- 2011
- Employees
- 7
- Programs
- 20
- Drugs
- 52
- Patents
- 138
Tovorafenib, Tovorafenib
Phase 2 · small molecule · craniopharyngioma
Tovorafenib, Tovorafenib for craniopharyngioma is a Phase 2 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AXIM BIOTECHNOLOGIES, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- craniopharyngioma
- Status
- active
- Trials
- 1